ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 178 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2018. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,080 | -15.8% | 26,248 | -4.4% | 0.00% | -33.3% |
Q1 2024 | $1,283 | -6.6% | 27,461 | -5.0% | 0.00% | 0.0% |
Q4 2023 | $1,373 | +40.1% | 28,905 | +5.1% | 0.00% | +50.0% |
Q3 2023 | $980 | +0.3% | 27,496 | +30.6% | 0.00% | 0.0% |
Q2 2023 | $977 | +23.4% | 21,048 | +6.7% | 0.00% | 0.0% |
Q1 2023 | $792 | -33.7% | 19,729 | -23.1% | 0.00% | -33.3% |
Q4 2022 | $1,195 | -99.7% | 25,660 | +162.2% | 0.00% | +200.0% |
Q3 2022 | $404,000 | +90.6% | 9,787 | +175.5% | 0.00% | 0.0% |
Q2 2022 | $212,000 | -20.9% | 3,553 | +2.0% | 0.00% | 0.0% |
Q1 2022 | $268,000 | -13.8% | 3,484 | -6.1% | 0.00% | 0.0% |
Q4 2021 | $311,000 | -5.8% | 3,710 | +1.9% | 0.00% | 0.0% |
Q3 2021 | $330,000 | -4.9% | 3,641 | 0.0% | 0.00% | 0.0% |
Q2 2021 | $347,000 | -22.5% | 3,641 | -8.3% | 0.00% | 0.0% |
Q1 2021 | $448,000 | -13.5% | 3,969 | +5.6% | 0.00% | 0.0% |
Q4 2020 | $518,000 | +67.6% | 3,759 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $309,000 | +5.5% | 3,759 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $293,000 | +74.4% | 3,759 | 0.0% | 0.00% | – |
Q1 2020 | $168,000 | +5.7% | 3,759 | 0.0% | 0.00% | – |
Q4 2019 | $159,000 | -64.3% | 3,759 | -46.6% | 0.00% | -100.0% |
Q2 2019 | $446,000 | -1.8% | 7,036 | +7.0% | 0.00% | 0.0% |
Q1 2019 | $454,000 | +102.7% | 6,576 | +23.1% | 0.00% | 0.0% |
Q4 2018 | $224,000 | -45.2% | 5,344 | 0.0% | 0.00% | 0.0% |
Q3 2018 | $409,000 | -0.5% | 5,344 | 0.0% | 0.00% | 0.0% |
Q2 2018 | $411,000 | +29.2% | 5,344 | -14.1% | 0.00% | 0.0% |
Q1 2018 | $318,000 | +10.4% | 6,219 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $288,000 | +29.1% | 6,219 | +50.3% | 0.00% | 0.0% |
Q3 2017 | $223,000 | -13.2% | 4,139 | 0.0% | 0.00% | 0.0% |
Q2 2017 | $257,000 | -8.2% | 4,139 | 0.0% | 0.00% | 0.0% |
Q1 2017 | $280,000 | -4.1% | 4,139 | 0.0% | 0.00% | 0.0% |
Q4 2016 | $292,000 | -50.2% | 4,139 | -50.0% | 0.00% | 0.0% |
Q3 2016 | $586,000 | +190.1% | 8,278 | +100.0% | 0.00% | 0.0% |
Q2 2016 | $202,000 | +24.7% | 4,139 | +62.0% | 0.00% | 0.0% |
Q1 2016 | $162,000 | -43.6% | 2,555 | 0.0% | 0.00% | 0.0% |
Q4 2015 | $287,000 | +16.2% | 2,555 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $247,000 | +34.2% | 2,555 | +41.9% | 0.00% | 0.0% |
Q2 2015 | $184,000 | +65.8% | 1,800 | 0.0% | 0.00% | – |
Q1 2015 | $111,000 | +40.5% | 1,800 | 0.0% | 0.00% | – |
Q4 2014 | $79,000 | – | 1,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
First Light Asset Management, LLC | 217,459 | $24,760,000 | 1.64% |
Motley Fool Asset Management LLC | 152,326 | $17,344,000 | 1.25% |
Rock Springs Capital Management LP | 450,000 | $51,237,000 | 1.12% |
AtonRa Partners | 21,017 | $2,393,000 | 1.07% |
SECTORAL ASSET MANAGEMENT INC | 112,200 | $12,775,000 | 0.97% |
EMERALD ADVISERS, LLC | 228,368 | $26,002,000 | 0.94% |
EMERALD MUTUAL FUND ADVISERS TRUST | 239,023 | $27,215,000 | 0.90% |
FEDERATED HERMES, INC. | 3,912,408 | $445,467,000 | 0.86% |
HealthCor Management, L.P. | 207,610 | $23,638,000 | 0.84% |
Atika Capital Management LLC | 66,000 | $7,515,000 | 0.65% |